NCT00034255已完成1 期
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients
GMP Endotherapeutics8 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2001年12月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 62
- 试验地点
- 8
研究概览
简要总结
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of intramuscular INGAP Peptide given for the first time in humans as a potential treatment for diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients meeting all of the following inclusion criteria at screening can be considered for admission to the study.
- •Stage 1 and Stage 2:
- •Male and female patients with, type 1 diabetes mellitus that are 18 through 70 years of age, or type 2 diabetes mellitus that are 30 through 70 years of age.
- •Patients who are insulin deficient and are diagnosed with type 1 or type 2 diabetes mellitus, and are currently well managed with insulin, with or without metformin.
- •Patients who have been on stable doses of insulin treatment for 90 days prior to study randomization.
排除标准
- •Patients meeting any of the following exclusion criteria at screening will not be enrolled in the study:
- •Patients with a history of any clinically significant retinopathy, symptomatic autonomic neuropathy, unstable angina, or kidney problems.
- •Patients with an uncontrolled or untreated significant pulmonary, neurological condition, or cardiovascular disease, including hypertension, congestive heart failure, angina, or peripheral vascular disease.
- •Patients who have received any investigational product within 30 days of admission into the study.
- •Patients with a history or clinical evidence of multiple organ autoimmune disorders.
- •Patients with a medical condition, serious intercurrent illness, or extenuating circumstance that would significantly decrease study compliance, including all prescribed follow-up.
- •Patients who are lactating and breastfeeding.
研究者
研究点 (8)
Loading locations...
相似试验
已完成
1 期
A Study of LY2495655 in Healthy SubjectsHealthy VolunteerNCT01341470Eli Lilly and Company47
已完成
1 期
A Study of Nipocalimab in Healthy Male and Female ParticipantsHealthyNCT04848558Janssen Research & Development, LLC89
已完成
2 期
Stem Cell Mobilization With Pegfilgrastim in Lymphoma and MyelomaMyelomaLymphomaNCT00794261Centre Leon Berard150
已完成
1 期
A Study of Baricitinib (LY3009104) in Healthy Chinese ParticipantsHealthyNCT02758613Eli Lilly and Company33
已完成
1 期
A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy ParticipantsHealthyNCT03723746Janssen Research & Development, LLC74